TAp63-miRNA-AURKA Axis as a Therapeutic Target for Cutaneous Squamous Cell Carcinoma.
TAp63-miRNA-AURKA Axis as a Therapeutic Target for Cutaneous Squamous Cell Carcinoma.
复制标题
DOI：
10.1158/0008-5472.can-20-1215
复制
发表时间：
2020-06-15
期刊：
影响因子：
11.2
通讯作者：
中科院分区：
文献类型：
--
作者：
尽管浸润性皮肤鳞状细胞癌的发病率不断增加，但其预后仍然很差，这主要是由于缺乏可靠的分子标记物可用于靶向治疗。通过遗传和蛋白质组学分析，Davis及其同事在本期《癌症研究》中将TAp 63及其下游靶向miRNA、miR-30 c-2* 和miR-497定义为能够抑制小鼠和人类皮肤鳞状细胞癌进展和转移的主要参与者。miR-30 c-2* 或miR-497的模拟物以及AURKA（miR-497靶标）的药理学抑制抑制异种移植小鼠模型中的肿瘤生长，提出TAp 63-miR-30 c-2*/miR-497-AURKA轴作为潜在的治疗靶标。
Despite increasing incidence rates, prognosis of invasive cutaneous squamous cell carcinoma remains poor, mainly due to lack of reliable molecular markers that can be used for targeted therapy. Through genetic and proteogenomic analyses, Davis and colleagues in this issue of Cancer Research define TAp63 and its downstream target miRNAs, miR-30c-2*, and miR-497 as major players that can suppress progression and metastasis of mouse and human cutaneous squamous cell carcinoma. Mimics of miR-30c-2* or miR-497, as well as pharmacologic inhibition of AURKA, a miR-497 target, suppress tumor growth in xenograft mouse models, proposing the TAp63–miR-30c-2*/miR-497–AURKA axis as a potential therapeutic target.